Four routes exist and they barely overlap. Manufacturer copay cards are built for people whose commercial plan already covers the drug. Manufacturer cash programs are built for people paying entirely out of pocket. Patient assistance is income tested. Discount platforms negotiate against retail pricing. Anyone enrolled in Medicare or Medicaid is excluded from commercial copay assistance outright.
Match the route to your actual status
Most frustration with savings offers comes from applying to the wrong one. The headline reduction advertised on a copay card assumes an insured patient whose plan covers anti-obesity medication and whose remaining share is a copay or coinsurance amount. Take away the coverage and the card has nothing to reduce, which is why uninsured applicants so often see a number that bears no resemblance to the advertisement.
The cash program is the route designed for that situation. Manufacturers now sell directly to self-paying patients at prices set below list, with their own conditions attached, typically around refill timing and continuous participation. Those conditions are the part worth reading, because falling out of the window can change what the next month costs.
Why government coverage disqualifies you from copay cards
This surprises people every time. Commercial copay assistance is generally unavailable to anyone enrolled in Medicare, Medicaid, TRICARE, or other federal health programs. The exclusion is not a manufacturer preference; it reflects federal rules restricting inducements tied to federally reimbursed items and services. It applies even when the federal plan is not paying for the drug in question.
Medicare adds a second layer. Part D has historically been restricted from covering products used only for weight loss, which is why coverage discussions for older adults tend to turn on whether a separate qualifying indication exists rather than on obesity treatment itself. Someone on Medicare therefore sits outside both the copay card lane and, frequently, the coverage lane.
What each program is and who it turns away
| Route | Built for | Commonly excluded |
|---|---|---|
| Manufacturer copay card | Commercially insured, drug already covered | Medicare, Medicaid, TRICARE, uninsured patients |
| Manufacturer cash program | Self-pay patients without coverage | Those needing refills outside the required window |
| Patient assistance program | Low-income, usually uninsured applicants | Applicants above the income threshold |
| Discount platform | Anyone paying retail cash | Nobody, but savings on brand-only drugs are limited |
| Bundled telehealth pricing | Self-pay patients wanting one recurring figure | Those who want brand product specifically |
Patient assistance is real but slow
Manufacturer patient assistance programs supply medication at no cost or reduced cost to applicants who meet income criteria, usually documented with tax returns and proof of residency. They are genuine, they are not advertised heavily, and they take weeks. Applications are also typically renewed annually rather than once.
Two practical notes. Approval is often tied to a specific prescriber who signs part of the form, so switching clinicians mid-application restarts things. And approval usually covers the medication only, not the visits or labs that come with it.
Where cash programs and bundled pricing fit
Discount platforms are worth thirty seconds of checking and rarely more than that. Their bargaining power comes from negotiating against pharmacy pricing, which is widest on generics and narrow on a brand-only product with no generic equivalent. Nothing is lost by running the search, but this is not usually the route that solves the problem.
Bundled telehealth pricing behaves differently from all of the above. There is no card, no insurer, and no income test. The recurring figure and the conditions attached to it are set by the provider behind it, and the medication dispensed is frequently compounded semaglutide rather than the brand. Compounded preparations are made by compounding pharmacies and are not FDA-approved products, so they carry neither approved labeling nor the trial evidence behind the brand. That is the trade being made, and it should be made deliberately rather than by default.
Dollars you may already have
Two sources get forgotten. Flexible spending and health savings accounts can generally be used for prescribed medication and for qualifying medical visits, which does not reduce the price but does change what it costs in after-tax terms. Employers are the second. A growing number of large employers carve out weight management benefits separately from the main pharmacy benefit, sometimes through a third-party vendor, and the benefit is easy to miss because it is not on the formulary document.
Sequence the applications properly
Coverage status first, because it determines which lane is open. Then the manufacturer program that matches that status. Then patient assistance if income qualifies, since it takes the longest and can run in parallel with a short-term route. Discount platforms last, as a check rather than a plan.
Guidelines for obesity pharmacotherapy treat these drugs as long-term therapy for a chronic condition, which makes the durability of a savings route more important than its opening figure. A route that works for three months and then expires is a bridge, not a solution, and it is worth knowing which one you are standing on.
For anyone whose status points to the bundled telehealth lane rather than a manufacturer card, the practical step is to line up the providers that post pricing openly. LillyDirect sells the brand direct, while Ro, Henry Meds, Hims and Hers, and HealthRX each publish self-pay terms; HealthRX sets out its Wegovy cost as one recurring figure, which is straightforward to hold against a manufacturer program that covers the drug alone. None of that replaces confirming eligibility on the card and assistance routes first.
Frequently asked questions
Can a copay card be used without insurance?
Generally not in a useful way. Copay assistance reduces the patient share of a covered claim, so with no covered claim there is nothing to apply it against. Uninsured patients are directed to the manufacturer cash program or to income-based assistance instead.
Why are Medicare patients turned down for savings cards?
Federal rules restrict manufacturer inducements to patients in federally funded health programs. The exclusion applies to enrollment in the program, not to whether the program pays for that particular drug, so it holds even when Part D covers nothing.
How long does patient assistance take?
Usually weeks rather than days, because applications require income documentation and a prescriber signature. Renewal is typically annual. Applying early and running another route in the meantime is the practical approach if treatment is starting soon.
Do savings programs cover the office visit and labs?
Almost never. Manufacturer programs address the medication only. Visit and lab costs stay with the patient unless a telehealth service has folded them into a single recurring charge, which is one of the main structural differences between the routes.
Is an older weight management drug a cheaper fallback?
Sometimes. Earlier agents such as liraglutide have their own labeling, dosing schedules, and pricing, and coverage rules differ. Effect sizes reported in trials also differ, so a lower price does not translate directly into a comparable result.
